busulfan has been researched along with Cancer, Second Primary in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD)." | 7.73 | Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. ( Andrèsen, S; Avalos, B; Bolwell, B; Copelan, E; Elder, P; Farag, S; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R; Wadehra, N, 2006) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD)." | 3.73 | Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. ( Andrèsen, S; Avalos, B; Bolwell, B; Copelan, E; Elder, P; Farag, S; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R; Wadehra, N, 2006) |
| "Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality." | 1.31 | Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. ( Benni, M; Cavo, M; Motta, MR; Rizzi, S; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2000) |
| "A case of hepatocellular carcinoma (HCC), which developed during chemotherapy for chronic myelogenous leukemia (CML), is presented." | 1.29 | Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report. ( Endo, Y; Hara, M; Katoh, M; Murashima, N; Nakajima, M; Takeuchi, K; Yamaguchi, H, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (26.67) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 6 (20.00) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Puckrin, R | 1 |
| Chua, N | 2 |
| Shafey, M | 1 |
| Stewart, DA | 2 |
| Andersson, BS | 1 |
| Thall, PF | 1 |
| Ma, J | 1 |
| Valdez, BC | 1 |
| Bassett, R | 1 |
| Chen, J | 1 |
| Ahmed, S | 1 |
| Alousi, A | 1 |
| Bashir, Q | 1 |
| Ciurea, S | 1 |
| Gulbis, A | 1 |
| Cool, R | 1 |
| Kawedia, J | 1 |
| Hosing, C | 1 |
| Kebriaei, P | 1 |
| Kornblau, S | 1 |
| Myers, A | 1 |
| Oran, B | 1 |
| Rezvani, K | 1 |
| Shah, N | 1 |
| Shpall, E | 1 |
| Parmar, S | 1 |
| Popat, UR | 1 |
| Nieto, Y | 1 |
| Champlin, RE | 1 |
| Long-Boyle, JR | 1 |
| Kohn, DB | 1 |
| Shah, AJ | 1 |
| Spencer, SM | 1 |
| Sevilla, J | 1 |
| Booth, C | 1 |
| López Lorenzo, JL | 1 |
| Nicoletti, E | 1 |
| Shah, A | 1 |
| Reatz, M | 1 |
| Matos, J | 1 |
| Schwartz, JD | 1 |
| Radujkovic, A | 1 |
| Hegenbart, U | 1 |
| Müller-Tidow, C | 1 |
| Herfarth, K | 1 |
| Dreger, P | 1 |
| Luft, T | 1 |
| Yu, SC | 1 |
| Huang, HH | 1 |
| Li, CC | 1 |
| Tang, JL | 1 |
| Lee, YH | 1 |
| Mao, TL | 1 |
| Kuo, KT | 1 |
| Lin, CT | 1 |
| Liu, JH | 1 |
| Ko, BS | 1 |
| Yao, M | 1 |
| Kato, M | 1 |
| Hasegawa, D | 1 |
| Koh, K | 1 |
| Kato, K | 2 |
| Takita, J | 1 |
| Inagaki, J | 1 |
| Yabe, H | 1 |
| Goto, H | 1 |
| Adachi, S | 1 |
| Hayakawa, A | 1 |
| Takeshita, Y | 1 |
| Sawada, A | 1 |
| Atsuta, Y | 1 |
| Oh, DH | 1 |
| Street, L | 1 |
| Douglas, G | 1 |
| Harrison, C | 1 |
| Forsyth, C | 1 |
| Bennett, M | 1 |
| Stevenson, W | 1 |
| Hounsell, J | 1 |
| Ratnasingam, S | 1 |
| Ritchie, D | 1 |
| Ross, DM | 1 |
| Grigg, A | 1 |
| Woo, HJ | 1 |
| Bai, CH | 1 |
| Kim, YD | 1 |
| Song, SY | 1 |
| Radaelli, F | 1 |
| Onida, F | 1 |
| Rossi, FG | 1 |
| Zilioli, VR | 1 |
| Colombi, M | 1 |
| Usardi, P | 1 |
| Calori, R | 1 |
| Zanella, A | 1 |
| Majhail, NS | 1 |
| Brazauskas, R | 1 |
| Rizzo, JD | 1 |
| Sobecks, RM | 1 |
| Wang, Z | 1 |
| Horowitz, MM | 1 |
| Bolwell, B | 2 |
| Wingard, JR | 1 |
| Socie, G | 1 |
| Lane, AA | 1 |
| McAfee, SL | 1 |
| Kennedy, J | 1 |
| Dube, C | 1 |
| Attar, EC | 1 |
| Ballen, KK | 1 |
| Dey, BR | 1 |
| Spitzer, TR | 1 |
| Chen, YB | 1 |
| Candoni, A | 1 |
| Tiribelli, M | 1 |
| Fanin, R | 1 |
| Ayas, M | 1 |
| Al-Seraihi, A | 1 |
| Al-Mahr, M | 1 |
| Al-Jefri, A | 1 |
| Belgaumi, A | 1 |
| Elhassan, I | 1 |
| El-Solh, H | 1 |
| Wadehra, N | 1 |
| Farag, S | 1 |
| Elder, P | 1 |
| Penza, S | 1 |
| Kalaycio, M | 1 |
| Avalos, B | 1 |
| Pohlman, B | 1 |
| Marcucci, G | 1 |
| Sobecks, R | 1 |
| Lin, T | 1 |
| Andrèsen, S | 1 |
| Copelan, E | 1 |
| Chang, C | 1 |
| Storer, BE | 1 |
| Scott, BL | 1 |
| Bryant, EM | 1 |
| Shulman, HM | 1 |
| Flowers, ME | 1 |
| Sandmaier, BM | 1 |
| Witherspoon, RP | 2 |
| Nash, RA | 1 |
| Sanders, JE | 1 |
| Bedalov, A | 1 |
| Hansen, JA | 1 |
| Clurman, BE | 1 |
| Storb, R | 2 |
| Appelbaum, FR | 2 |
| Deeg, HJ | 2 |
| Brandt, L | 1 |
| Anderson, H | 1 |
| Katoh, M | 1 |
| Takeuchi, K | 1 |
| Murashima, N | 1 |
| Nakajima, M | 1 |
| Yamaguchi, H | 1 |
| Endo, Y | 1 |
| Hara, M | 1 |
| Franco, E | 1 |
| Alvarez, R | 1 |
| Cuesta, I | 1 |
| Aguilar, C | 1 |
| Iurlo, A | 1 |
| Foa, P | 1 |
| Sala, M | 1 |
| Maiolo, AT | 1 |
| Fetscher, S | 1 |
| Finke, J | 1 |
| Engelhardt, R | 1 |
| Mertelsmann, R | 1 |
| Lange, W | 1 |
| Lemoli, RM | 1 |
| Visani, G | 1 |
| Leopardi, G | 1 |
| Motta, MR | 2 |
| Rizzi, S | 2 |
| Testoni, N | 1 |
| Curti, A | 1 |
| Tura, S | 2 |
| Randi, ML | 3 |
| Fabris, F | 3 |
| Girolami, A | 3 |
| Tosi, P | 1 |
| Zamagni, E | 1 |
| Ronconi, S | 1 |
| Benni, M | 1 |
| Cavo, M | 1 |
| Finazzi, G | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 1 |
| Storer, B | 1 |
| Anasetti, C | 1 |
| Bordigoni, P | 1 |
| Turello, R | 1 |
| Clement, L | 1 |
| Lascombes, P | 1 |
| Leheup, B | 1 |
| Galloy, MA | 1 |
| Plenat, F | 1 |
| Majado, MJ | 1 |
| González García, C | 1 |
| Marín-Blazquez, MD | 1 |
| Morales Lázaro, A | 1 |
| Moreno Moreno, M | 1 |
1 review available for busulfan and Cancer, Second Primary
| Article | Year |
|---|---|
Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 2004 |
3 trials available for busulfan and Cancer, Second Primary
| Article | Year |
|---|---|
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 2022 |
Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase.
Topics: Adult; Aged; Allografts; Autografts; Busulfan; Disease-Free Survival; Female; Hematologic Diseases; | 2017 |
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
26 other studies available for busulfan and Cancer, Second Primary
| Article | Year |
|---|---|
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous S | 2022 |
Busulfan and subsequent malignancy: An evidence-based risk assessment.
Topics: Adult; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leuk | 2024 |
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; | 2020 |
Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cel
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 2015 |
Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined | 2016 |
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Drug Resistance, Neoplasm; Drug Tolerance; Female; Foll | 2017 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepiderm | 2009 |
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Busulfan; Drug Therapy, Combination; | 2008 |
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cohort Studies; | 2011 |
High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma.
Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Myeloa | 2011 |
The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 2006 |
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality | 2006 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Pre | 2007 |
Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?
Topics: Administration, Oral; Aged; Busulfan; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukemi | 1995 |
Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report.
Topics: Busulfan; Carcinoma, Hepatocellular; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver | 1994 |
[Chronic myeloid leukemia (CML) and solid neoplasms. Description of 3 cases].
Topics: Aged; Breast Neoplasms; Busulfan; Carcinoma, Hepatocellular; Combined Modality Therapy; Fatal Outcom | 1994 |
Renal cancer after busulphan treatment for chronic myeloid leukemia. A case report.
Topics: Busulfan; Humans; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle A | 1993 |
Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclop | 1997 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod | 1999 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; | 1999 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; | 2000 |
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Surv | 2001 |
Second malignancies in patients with essential thrombocythaemia.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; | 2002 |
Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases.
Topics: Actuarial Analysis; Acute Disease; Bone Neoplasms; Busulfan; Child; Child, Preschool; Cranial Irradi | 2002 |
[Appearance of a chronic myeloid leukemia in Waldenström's macroglobulinemia].
Topics: Busulfan; Chlorambucil; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; | 1992 |